Menu
Search
|

Menu

Close
X

Paratek Pharmaceuticals Inc PRTK.OQ (NASDAQ Stock Exchange Global Market)

13.35 USD
+0.15 (+1.14%)
As of Feb 24
chart
Previous Close 13.20
Open 13.25
Volume 69,245
3m Avg Volume 88,734
Today’s High 13.40
Today’s Low 12.95
52 Week High 29.00
52 Week Low 11.90
Shares Outstanding (mil) 27.76
Market Capitalization (mil) 705.13
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.22 Mean rating from 9 analysts

KEY STATS

Revenue (mm, USD)
FY17
8
FY16
0
FY15
0
EPS (USD)
FY17
-1.808
FY16
-5.670
FY15
-4.228
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
93.26
5.77
Price to Book (MRQ)
vs sector
6.18
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
43.29
16.52
LT Debt to Equity (MRQ)
vs sector
43.29
12.22
Return on Investment (TTM)
vs sector
-64.38
14.43
Return on Equity (TTM)
vs sector
-87.28
16.13

EXECUTIVE LEADERSHIP

Michael Bigham
Chairman of the Board, Chief Executive Officer, Since 2014
Salary: $425,000.00
Bonus: --
Evan Loh
President, Chief Operating Officer, Chief Medical Officer, Director, Since 2017
Salary: $415,000.00
Bonus: --
Douglas Pagan
Chief Financial Officer, Since 2014
Salary: $325,000.00
Bonus: $22,750.00
William Haskel
Senior Vice President, General Counsel, Corporate Secretary, Since 2015
Salary: $336,500.00
Bonus: $23,555.00
Jeanne Jew
Senior Vice President - Business Development, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

75 Park Plz Ste 4
BOSTON   MA   02116-3934

Phone: +1617.8076600

Paratek Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections. Sarecycline is a tetracycline-derived compound designed for use in the treatment of acne and rosacea. Its other product candidates are tetracycline-derived, molecular entities and are designed to utilize the recognized immune-modulation, anti-inflammatory and other beneficial properties of the tetracycline class. These research stage programs include product candidates for multiple sclerosis, spinal muscular atrophy, systemic inflammatory diseases, such as rheumatoid arthritis and inflammatory bowel diseases.

SPONSORED STORIES